Pipeline

Commercialized Products

TAVALISSE® (fostamatinib)1

Adult Chronic Immune Thrombocytopenia
Target: Spleen tyrosine kinase (SYK)

Pre-Clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-Clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

REZLIDHIA® (olutasidenib)2

R/R mIDH1 Acute Myeloid Leukemia
Target: Mutant isocitrate dehydrogenase–1 (mIDH1)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

GAVRETO® (pralsetinib)3

RET+ Non-Small Cell Lung Cancer & Advanced Thyroid Cancer
Target: Rearranged During Transfection (RET)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
REGISTRATIONAL Complete
Approved Complete

Clinical Trials

R289*

Lower-Risk Myelodysplastic Syndrome
Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Not Started
REGISTRATIONAL Not Started
Approved Not Started

Partnered Programs4

Ocadusertib* (Systemic) – Eli Lilly

Rheumatoid Arthritis
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Pre-clinical Phase 1 Phase 2 REGISTRATIONAL Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 In Progress
REGISTRATIONAL Not Started
Approved Not Started

KEY:

Company-sponsored Trials Partnered Programs

1 Please see the TAVALISSE Full Prescribing Information

2 Please see the REZLIDHIA Full Prescribing Information, including Boxed WARNING

3 Please see the GAVRETO Full Prescribing Information

4 Rigel also has partnerships with BerGenBio (bemcentinib) and Daiichi Sankyo (milademetan)

* Investigational compound - has not been submitted for approval by FDA